Mylan group sued over for first-to-file ANDAs
US generic drug major Mylan says that it and/or a subsidiary have been sued in connection with four separate first-to-file Abbreviated New Drug Applications filed with the US Food and Drug Administration.
Mylan and Alphapharm Pty were sued by Sepracor in the US District Court of New Jersey with regard to the ANDA filing for eszopiclone tablets, 1mg, 2mg and 3mg, the generic version of Sepracor's insomnia drug Lunesta, which had US sales of around $796.0 million for the 12 months to December 31, 2008, according to IMS Health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze